Company research / TECX

Tectonic Therapeutic, Inc. (TECX)

CIK 0001681087 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated NY
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-29.5%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-32, first reflected in a filing dated 2025-03-20. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
R&D Expense$72.19M$63.49M$41.36M$36.97M$72.19M$83.11M$87.24M$54.97M$35.09M$15.19M
Operating Income-$94.92M-$84.04M-$58.02M-$44.65M-$105.43M-$118.84M-$120.23M-$75.81M-$46.24M-$18.39M
Depreciation & Amortization$1.26M$1.38M$1.65M$1.48M$1.44M$1.40M$1.21M$850.0K$380.0K$45.0K
EBITDA-$93.66M-$82.66M-$56.37M-$43.17M-$103.99M-$117.44M-$119.02M-$74.96M-$45.86M-$18.34M
Net Income-$85.79M-$74.15M-$57.98M-$42.82M-$105.89M-$119.13M-$119.71M-$72.97M-$46.36M-$18.65M
EPS (Diluted)n/a-$4.05-$6.83-$33.76-$2.42-$2.78n/an/an/an/a
Total Assets$237.03M$261.04M$152.91M$39.40M$103.95M$203.84M$271.23M$200.51M$133.48M$7.02M
Total Liabilities$13.19M$9.71M$12.13M$43.41M$28.58M$34.36M$16.89M$14.50M$11.29M$3.66M
Long-Term Debtn/an/an/an/a$15.00M$15.00Mn/an/an/an/a
Shareholders' Equity$223.85M$251.33M$140.78M-$84.64M$75.37M$169.48M$254.34M$186.01M$122.18M-$23.14M
Cash & Equivalents$227.07M$253.80M$141.24M$28.77M$92.56M$189.57M$259.68M$187.04M$126.30M$5.96M
Operating Cash Flow-$72.14M-$60.08M-$59.08M-$40.68M-$97.21M-$98.03M-$98.80M-$67.67M-$37.65M-$16.38M
Capital Expenditures$279.0K$208.0K$156.0K$279.0K$267.0K$2.46M$1.18M$1.58M$1.83M$383.0K
Free Cash Flow-$72.42M-$60.29M-$59.24M-$40.96M-$97.47M-$100.49M-$99.98M-$69.25M-$39.48M-$16.77M
Shares Outstanding19.24M18.74M14.86M1.41M43.92M43.65M43.65M31.64M23.81M2.31M
Dividends Per Sharen/a$0.00$0.00n/an/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a18.32M8.49M1.27M43.74Mn/an/an/an/an/a
EPS (Basic)n/a-$4.05-$6.83-$33.76-$2.42-$2.78n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView